A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease

Inclusion criteria: * Male or female participants 40 - 85 years of age. * Willing and able to give informed consent (including through use of a legally authorized representative (LAR), if necessary). * Idiopathic PD, per UK Parkinson's Disease Society (UKPDS) Brain Bank Clinical Diagnostic Criteria * ON motor MDS UPDRS \>20. * Anti-parkinsonian medication is fixed for at least one month prior to the day the participant starts study drug treatment. * If MoCA\<22 participant must have a designated caregiver that agrees to ensure study protocols followed. This includes accompanying patient to study visits and being available for study phone calls. * Must have a driver or available transportation (including provided Uber vouchers) to drive them to and from study visits and for other transportation needs during the treatment period. * Has a significant other (someone who knows the participant well) that is appropriate for doing the NPI assessment, and agrees to do so * Agrees to not take more than 1 gram per day of acetaminophen, due to a possible interaction with study drug that could increase risk of hepatotoxicity. Exclusion criteria: * Known or suspected allergy to cannabinoids or excipients used in the study drug formulation. * Cannabis is detectable at the screening visit by blood testing or at the baseline visit by urine testing. If cannabis is detected at either the screening or baseline visit, then the participant is a screen fail and may return \>14 days later for a r…